Bavarian Nordic A/S (BVNRY)
| Previous Close | 8.38 |
| Open | 8.63 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 8.63 - 8.67 |
| 52 Week Range | 5.95 - 10.65 |
| Volume | |
| Avg. Volume | 4,153 |
| Market Cap | 2.036B |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | 14.18 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 27, 2020 |
| 1y Target Est | N/A |
- Reuters
UPDATE 2-US CDC recommends routine use of Bavarian Nordic mpox vaccine for adults at risk
Danish pharmaceutical company Bavarian Nordic said on Wednesday a U.S. Centers for Disease Control and Prevention panel has voted in favor of recommending the routine use of Jynneos vaccine for adults at risk of mpox. The CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend that individuals 18 years and older with certain risk factors should receive two doses of Jynneos. The panel had previously recommended the vaccine for individuals at risk of mpox only during an outbreak, Bavarian said.
- Reuters
UPDATE 1-Bavarian Nordic ends RSV vaccine programme after poor trial results
Denmark-based Bavarian Nordic said on Saturday it was ending its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease. RSV is a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalisation. The market for RSV vaccines could exceed $10 billion by 2030, according to analysts.
